S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
S&P 500   3,841.47
DOW   30,996.98
QQQ   325.42
Log in
CNSX:RKS

Rockshield Capital Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range
$0.04
MA: $0.04
$0.06
52-Week Range N/A
Volume10,000 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Rockshield Capital Corp. is a venture capital firm specializing in early-stage, seed and emerging growth investments. The firm seeks to invest at various stages of development, including pre-initial public offering, and/or early stage companies requiring start-up or development capital. The firm seeks to invest in marketable securities comprising common shares and other equity instruments of companies in the mining, oil and gas, media technology, and medical technology industries that are listed on various Canadian stock exchanges or the OTCBB in the United States. It considers to invest over a number of sectors, including but not limited to: cannabis, fintech, healthcare, the resource sector, information and communications technology, and energy & clean technology. The firm seeks to invest between $0.25 million to $2 million. The firm is also involved in assisting financing, identifying acquisition targets, developing strategic plans, supporting operations, and implementing exit strategies. The firm also works with co-investors. It typically invests in Canada and the United States. Rockshield Capital Corp. was founded in 2007 and is based in Vancouver, Canada.

MarketRank

Overall MarketRank

0.54 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Asset Management
Sub-IndustryN/A
CUSIPN/A
CIKN/A
Phone604-315-1237
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable
30 days | 90 days | 365 days | Advanced Chart

Receive RKS News and Ratings via Email

Sign-up to receive the latest news and ratings for RKS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Rockshield Capital (CNSX:RKS) Frequently Asked Questions

What stocks does MarketBeat like better than Rockshield Capital?

Wall Street analysts have given Rockshield Capital a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Rockshield Capital wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of Rockshield Capital's key competitors?

What other stocks do shareholders of Rockshield Capital own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rockshield Capital investors own include OrganiGram (OGI), INSYS Therapeutics (INSY), Concordia International Corp. (CXR.TO) (CXR) and Aurora Cannabis (ACBFF).

Who are Rockshield Capital's key executives?

Rockshield Capital's management team includes the following people:
  • Mr. David James Doherty, Founder, Pres, CEO & Director (Age 46)
  • Mr. Nick DeMare C.A., CPA, CPA, CA, CFO, Corp. Sec. & Director (Age 65)

What is Rockshield Capital's stock symbol?

Rockshield Capital trades on the CNSX under the ticker symbol "RKS."

How do I buy shares of Rockshield Capital?

Shares of RKS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Rockshield Capital's official website?

The official website for Rockshield Capital is www.rockshield.ca.

How can I contact Rockshield Capital?

The company can be reached via phone at 604-315-1237.

This page was last updated on 1/23/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.